E-Z-EM to access new contrast technology
X-ray contrast firm E-Z-EM hopes to develop new imaging agentsbased on microsphere technology it has licensed from InteractiveMedical Technologies. E-Z-EM, of Westbury, NY, has an option onan exclusive license for all applications of the technology,
X-ray contrast firm E-Z-EM hopes to develop new imaging agentsbased on microsphere technology it has licensed from InteractiveMedical Technologies. E-Z-EM, of Westbury, NY, has an option onan exclusive license for all applications of the technology, includingultrasound detection of pulmonary embolism and myocardial ischemia.The agreement also includes global sales and marketing of productsbased on the technology.
Interactive Medical Technologies has developed albumin-basedmicrospheres, which can be manufactured in sizes as small as onemicron. Under the terms of the agreement, E-Z-EM will begin preclinicalsafety testing of the microspheres at Dartmouth Medical Schoolin Hanover, NH, and the company will also analyze the regulatorycosts for conducting additional clinical trials.
"E-Z-EM is especially interested in this unique technologyas it could relate to various imaging applications in our targetmarkets," said E-Z-EM president and CEO Daniel Martin. "Contrastmicrospheres could have applications in enhancing the measurementof blood flow by ultrasound."
In other E-Z-EM news, the company in February introduced anew barium sulfate contrast agent for CT exams of the abdomenand pelvis. The new product will be marketed as E-Z-CAT Dry.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
